Modality
ERT
MOA
IL-13i
Target
LAG-3
Pathway
STING
AngelmanRCCNSCLC
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
Dec 2023
→ Feb 2029
Phase 2Current
NCT05816061
156 pts·Angelman
2023-12→2029-02·Not yet recruiting
156 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-102.9y awayPh3 Readout· Angelman
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2/3
Not yet…
Catalysts
Ph3 Readout
2029-02-10 · 2.9y away
Angelman
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05816061 | Phase 2/3 | Angelman | Not yet recr... | 156 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| ALN-6288 | Alnylam | Approved | LAG-3 |